Additional in vitro and in vivo studies are needed to determine the cause of the specificity of JAK2V617F for myeloid diseases, as second mutations, host modifiers, differential cytokine receptor expression, and other factors may influence the ultimate phenotype of hematopoietic progenitors that acquire the JAK2V617F mutation. (bloodjournal.org)
The scientists found this second mutation lowers levels of a naturally - occurring antioxidant called glutathione. (sciencedaily.com)
But until now scientists only partially understood how this second mutation allowed the cancer cells to protect themselves against erlotinib. (sciencedaily.com)